DLL3 and small cell lung carcinoma: Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against DLL3; its activity has been assessed in a phase I study including SCLC and LCNEC pretreated patients, showing an ORR of 18% and a manageable safety profile (123).